Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 11.02.2019 | 14:27

Biofrontera AG: Biofrontera implements new Falsified Medicines Directive

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous

11.02.2019 / 14:27
The issuer is solely responsible for the content of this announcement.


Biofrontera implements new Falsified Medicines Directive

Leverkusen, Germany, February 11, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, has implemented all necessary safety measures defined in the new Commission Delegated Regulation (EU) 2016/161 to fight medicine falsifications. Since the Regulation came into force on February 9, 2019, only prescription drugs for human use with the safety features of the Commission Delegated Regulation (EU) 2016/161 may be released for marketing. Product batches released before February 9, 2019 may still be sold.

"The implementation of the Falsified Medicines Directive throughout the pharmaceutical supply chain will contribute to one thing in particular: the safety of prescription drugs. The safety standard is already at a very high level in Germany, but is being driven even further by the EU-wide laws," explains Prof. Dr. Lübbert, CEO of Biofrontera AG. "With the new Regulation, a further and significantly higher hurdle has now been created for drug counterfeiters. Patients will now be even better protected against counterfeit drugs of low quality or incorrect dosage of active substances".

The Commission Delegated Regulation (EU) 2016/161 essentially provides for the introduction of two security features. A unique identifier in form of a serialized number combined with a product code, batch number and expiry date make each package unique and individually identifiable. A so-called "anti-tampering device" protects the outer packaging against manipulation and allows verification of whether the packaging has been tampered with before the first use.

-End-

 

For enquiries, please contact:

Biofrontera AG


Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0

ir@biofrontera.com
IR UK: Seton Services

Toni Vallen
+44 (0) 207 224 8468
IR and PR US: The Ruth Group

IR: Tram Bui

PR: Kirsten Thomas
+1 646-536-7035

+1 508-280-6592
 

 

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.



11.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Syzygy AG: EBIT-Prognose überfüllt, weiteres Wachstum in Sicht

Mit einer erneut außerordentlich guten Entwicklung der in Deutschland ansässigen Tochtergesellschaften war der SYZYGY-Konzern in der Lage, die Umsatzbasis auf 65,82 Mio. EUR (VJ: 60,67 Mio. EUR) auszubauen. Das Zuwachs von 8,5 % liegt leicht unter der ursprünglichen Unternehmens-Guidance eines zweistelligen Umsatzwachstums. Die Prognose einer EBIT-Marge im oberen einstelligen Bereich wurde aber voll erfüllt. Auf Basis der erreichten Neukundengewinne prognostiziert das Unternehmensmanagement für 2019 ein Umsatzwachstum in einem hohen einstelligen Prozentbereich. Das EBIT sollte um rund 10 % und damit überproportional ansteigen. Unsere Analysten sind weiter positiv für das Unternehmen mit einem Kursziel von 12,15 EUR je Aktie.

News im Fokus

Deutsche Post AG: Deutsche Post AG nimmt Stellung zur beabsichtigten Entscheidung zur Preisregulierung

18. April 2019, 11:19

Aktuelle Research-Studie

SAF-HOLLAND S.A.

Original-Research: SAF-Holland S.A. (von Montega AG): Kaufen

18. April 2019